Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Atopic Dermatitis is an itchy inflammation of skin. Signs and symptoms of Atopic Dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
The Atopic Dermatitis – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.
Key Targets in the Atopic Dermatitis Pipeline Drugs Market
The key targets in the Atopic Dermatitis pipeline drugs market are Phosphodiesterase 4, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Filaggrin, Liver X Receptor, 16S Ribosomal RNA, Angiopoietin 1 Receptor, and Caspase 1 among others.
Atopic Dermatitis Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Atopic Dermatitis Pipeline Drugs Market
The key mechanisms of action in the Atopic Dermatitis pipeline drugs market are Phosphodiesterase 4 Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 13 Inhibitor, Sphingosine 1-Phosphate Receptor 1 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor among others.
Atopic Dermatitis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Atopic Dermatitis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Atopic Dermatitis pipeline drugs market are Topical, Subcutaneous, Intravenous, Oral, Inhalational, Rectal, Ophthalmic, and Parenteral.
Atopic Dermatitis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Atopic Dermatitis Pipeline Drugs Market
The key molecule types in the Atopic Dermatitis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Synthetic Peptide, and Biologic among others.
Atopic Dermatitis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Atopic Dermatitis Pipeline Drugs Market
The major companies in the Atopic Dermatitis pipeline drugs market are Pfizer Inc, Bristol-Myers Squibb Co, Dermavant Sciences Inc, AstraZeneca Plc, JiangSu Qyuns Therapeutics Co Ltd, Leo Pharma AS, MD Healthcare Inc, Union Therapeutics AS, 3SBio Inc, and Aslan Pharmaceuticals Ltd among others.
Atopic Dermatitis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Atopic Dermatitis Pipeline Drugs Market Overview
Key Targets | Phosphodiesterase 4, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Filaggrin, Liver X Receptor, 16S Ribosomal RNA, Angiopoietin 1 Receptor, and Caspase 1 |
Key Mechanisms of action | Phosphodiesterase 4 Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 13 Inhibitor, Sphingosine 1-Phosphate Receptor 1 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor |
Key Routes of Administration | Topical, Subcutaneous, Intravenous, Oral, Inhalational, Rectal, Ophthalmic, and Parenteral |
Key molecule types | Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Synthetic Peptide, and Biologic |
Major companies | Pfizer Inc, Bristol-Myers Squibb Co, Dermavant Sciences Inc, AstraZeneca Plc, JiangSu Qyuns Therapeutics Co Ltd, Leo Pharma AS, MD Healthcare Inc, Union Therapeutics AS, 3SBio Inc, and Aslan Pharmaceuticals Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Atopic Dermatitis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Abate Med Inc
AbbVie Inc
Aclaris Therapeutics Inc
Adare Pharma Solutions
Akaal Pharma Pty Ltd
Akeso Inc
Alexion Pharmaceuticals Inc
Allakos Inc
Allergy Therapeutics Plc
Almirall SA
Amgen Inc
Amicogen Inc
Amorepacific Corp
Amtixbio Co Ltd
Amytrx Therapeutics Inc
Annji Pharmaceutical Co Ltd
AOBiome LLC
Apimeds Inc
Arcutis Biotherapeutics Inc
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atrapos Therapeutics LLC
Attillaps Holdings Inc
Avixgen Inc
Azitra Inc
Bausch Health Companies Inc
Beijing Puqi Pharmaceutical Technology Co Ltd
BenevolentAI Ltd
BioMarck Pharmaceuticals Ltd
BioMe Inc
Biomimetix JV LLC
BiomX Inc
Biosion Inc
Bioversys AG
Biozeus Pharmaceutical SA
Blueberry Therapeutics Ltd
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Botanix Pharmaceuticals Ltd
Brandenburg Antiinfektiva GmbH
Brexogen Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Cellivery Therapeutics Inc
CELLnLIFE Inc
Chugai Pharmaceutical Co Ltd
Clayton Biotechnologies Inc
Clevexel Pharma SA
CSA Biotechnologies LLC
Cugene Inc
Curexsys GmbH
Cutanea Life Sciences Inc
Daiichi Sankyo Co Ltd
Derm-Biome Pharmaceuticals Inc
Dermala Inc
Dermavant Sciences Inc
DermBiont Inc
Devonian Health Group Inc
DongKoo Bio & Pharma Co Ltd
EHL Bio Co Ltd
Eli Lilly and Co
Emerald Biotechnology Espana
Enitiate Biopharmaceuticals (Hangzhou) Co Ltd
Enzychem Lifesciences Corp
Epigen Biosciences Inc
Evelo Biosciences Inc
Evommune Inc
Evotec SE
F. Hoffmann-La Roche Ltd
Galapagos NV
General Regeneratives Shanghai Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
GI Innovation Co Ltd
GL Pharm Tech Corp
GlaxoSmithKline Plc
Hefei Medical & Pharmaceutical Co Ltd
Hill Dermaceuticals Inc
Hoth Therapeutics Inc
Huons Co Ltd
Ichnos Sciences Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Ingenew Pharmaceuticals Inc
Inmagene Biopharmaceuticals Ltd
InnoCare Pharma Ltd
InnoPharmaScreen Inc
Innovation Pharmaceuticals Inc
Innovimmune Biotherapeutics Inc
Integral Molecular Inc
Intrinsic Medicine Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Jupiter Wellness Inc
JW Pharmaceutical Corp
Kangstem Biotech Co Ltd
KeyMed Biosciences Inc
Kine Sciences
Kiniksa Pharmaceuticals Ltd
KoBioLabs Inc
Krystal Biotech Inc
Kymab Ltd
Kymera Therapeutics, Inc
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Lanier Biotherapeutics Inc
Larix Bioscience LLC
Lead Pharma Holding BV
Leo Pharma AS
LG Chem Ltd
Liminal BioSciences Inc
Lipidor AB
Lynk Pharmaceutical Hangzhou Co Ltd
Mabwell Shanghai Bioscience Co Ltd
Maruho Co Ltd
Matrisys Bioscience Inc
MC2 Therapeutics AS
MD Healthcare Inc
Medicenna Therapeutics Corp
Micreos BV
Midatech Pharma Plc
Minghui Pharmaceutical (Shanghai) Co Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nektar Therapeutics
Neovacs SA
Nepsone ehf
Neuracle Science Co Ltd
Next Science Ltd
NextPhase Therapeutics
NovaCell Technology Inc
Novan Inc
NovaRock Biotherapeutics Inc
Novartis AG
Numab Therapeutics AG
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
OM Pharma Ltd
Oncocross Co Ltd
Ondek Pty Ltd
Oneness Biotech Co Ltd
Orgenesis Inc
Otsuka Pharmaceutical Co Ltd
Panolos Bioscience
Pantherics Inc
PeLeMed Co Ltd
Pfizer Inc
PrimeGen Global Inc
Principia Biopharma Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Qurient Co Ltd
Ralexar Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Regeneus Ltd
Regranion LLC
Rhizen Pharmaceuticals SA
Ribomic Inc
Ribon Therapeutics Inc
Rudacure Co Ltd
Sanofi
SCM lifescience Co Ltd
Seanergy Dermatology Ltd
Seelos Therapeutics, Inc.
Servatus Ltd
Shandong Boan Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Maiji Biotechnology Co Ltd
Shaperon Inc
Shenzhen Forward Pharmaceutical Co Ltd
Shulov Innovative Science Ltd
Signum Biosciences Inc
Signum Dermalogix Inc
Siolta Therapeutics Inc
siRNAgen Therapeutics Corp
Sosei Group Corp
StemRIM Inc
Sun Pharmaceutical Industries Ltd
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Longbote Pharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Technoderma Medicines Inc
Temisis Therapeutics
TeraImmune Inc
Teres Bio Inc
The Geneva Biotech Center SA
The United Laboratories International Holdings Ltd
Therabest Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tirmed Pharma AB
Torrent Pharmaceuticals Ltd
Transdermal Therapeutic Technologies LLC
TRPblue Inc
TWi Biotechnology Inc
UCB SA
Union Therapeutics AS
United Biomedical Inc
Vasomune Inc
vTv Therapeutics Inc
VYNE Therapeutics Inc
Welichem Biotech Inc
YIRUI Pharmaceutical Technology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Atopic Dermatitis pipeline drugs market?
The key targets in the Atopic Dermatitis pipeline drugs market are Phosphodiesterase 4, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Filaggrin, Liver X Receptor, 16S Ribosomal RNA, Angiopoietin 1 Receptor, and Caspase 1.
-
What are the key mechanisms of action in the Atopic Dermatitis pipeline drugs market?
The key mechanisms of action in the Atopic Dermatitis pipeline drugs market are Phosphodiesterase 4 Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 13 Inhibitor, Sphingosine 1-Phosphate Receptor 1 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor.
-
What are the key routes of administration in the Atopic Dermatitis pipeline drugs market?
The key routes of administration in the Atopic Dermatitis pipeline drugs market are Topical, Subcutaneous, Intravenous, Oral, Inhalational, Rectal, Ophthalmic, and Parenteral.
-
What are the key molecule types in the Atopic Dermatitis pipeline drugs market?
The key molecule types in the Atopic Dermatitis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Cell Therapy, Synthetic Peptide, and Biologic.
-
What are the major companies in the Atopic Dermatitis pipeline drugs market?
The major companies in the Atopic Dermatitis pipeline drugs market are Pfizer Inc, Bristol-Myers Squibb Co, Dermavant Sciences Inc, AstraZeneca Plc, JiangSu Qyuns Therapeutics Co Ltd, Leo Pharma AS, MD Healthcare Inc, Union Therapeutics AS, 3SBio Inc, and Aslan Pharmaceuticals Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.